tbuckley/cabot-search huggingface dataset:
PARE0015 Rheumatism – the Invisible Disease. A Project of Young People with Arthritis in Germany, That Became A Campaigne without Limits
Authors: B. Teutriene
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Young people with arthritis in Germany already developed in 2010 a project to show how they have to deal with a pronounced lack of understanding according their disease ("Journey in the dark", presented 2011 at EULAR congress in London). In connection to the demands of the "German Action Plan For Young People With RMDs" of 2012 (presented 2013 in Madrid) they now developed a new, extended project for public occasions. <h3>Objectives</h3> The committee of young people with arthritis in Germany wanted to be able to make their restrictions sensible for everyone and underline their demands of better supports in public, even if the disease is not visible at once. <h3>Methods</h3> The young people with arthritis of Germany created an interactive event which was presented as a marketing strategy at a shopping mall in Berlin in October 2012. They designed four tables, where interested people, who came along, were invited to feel the limitations and difficulties rheumatism includes. After visiting all tables interested people got some general information of RMDs with highlighting information about the German Action Plan for Young People with RMDs. The event was filmed in order to document it. A guideline was created, in order to simplify implementation of future events. <h3>Results</h3> The people who visited the different tables were very impressed and said that they now had basis knowledge of RMDs, its limitations and especially problems of young people with this disease in their daily life. Their reactions have been documented in the film as well. The project has received a scholarship in Germany (www.startsocial.de). <h3>Conclusions</h3> "Rheumatism – The invisible disease" is a unique way of making the situation of young and old people with arthritis not only visible but also sensible to others. The project managed to motivate people with arthritis in whole Germany to try similar ways of showing their problems and to help create a better understanding for their situation. "Rheumatism - The invisible disease" toured through Germany the last year and will be shown at many other different occasions during the coming years. It became a campaign of the whole "Deutsche Rheuma-Liga" without limitations in age or kind of disease. <h3>References</h3> Rheumatism – The invisible disease. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1263
Abstract 5615: Combination therapy for chronic myelogenous leukemia: Targeting the BCR-ABL coiled-coil domain and other pathways for synthetic lethality
Authors: David W. Woessner, Carol S. Lim
Journal: Cancer Research (2012)

Abstract Single-agent tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) has been largely effective in keeping the disease at bay. However, resistance to therapy and persistence of a subset of leukemic cells demonstrate the necessity for multiple-agent therapy. We have developed a unique interfering peptide, CCmut2 (Dixon et al., JBC 2011) able to disrupt BCR-ABL dimers. This disruption of trans-auto phosphorylation exacts its activity via the coiled-coil domain in BCR, but leads to an overall similar effect as TKIs - induction of apoptosis and reduction in proliferation. Here we detail the results of this peptide (delivered as a gene and transcribed in vitro) in combination with small molecule or biologic agents. The secondary agents include: chloroquine which is used to inhibit lysosomal acidification and block cellular macroautophagy; zileuton, a specific inhibitor of arachidonate 5-lipoxygenase (Alox5) known to enhance the proliferative capacity of CML cells; and GO-201, an interfering peptide targeting MUC-1, a known oncogene expressed in CML cells. These agents in combination with CCmut2 were hypothesized to improve therapeutic potency and enhance leukemia-specific cytotoxicity. All assays were performed in BCR-ABL expressing K562 cells in vitro. Western blots confirming knockdown of the autophagy gene ATG7, Alox5, and MUC-1 using shRNA were carried out. The autophagy pathway was further validated by blotting for autophagic microtubule-associated protein light chain 3 (LC3) conversion from LC3-I to LC3-II following combination therapy with CCmut2 and chloroquine. Transformative ability of K562 cells was evaluated using a methylcellulose colony forming assay following co-transfection with CCmut2 and a shRNA. Next, the specific drugs targeting these pathways were also used in combination with the CCmut2 and assessed for apoptotic potential using caspase 3/7 activity and DNA segmentation. Proliferation was investigated using trypan blue exclusion and transformative ability was further assessed with multi-drug combinations. MUC-1 inhibition in combination with CCmut2 resulted in a potent combination in K562 cells. Other combinations hinted at an additive or synergistic enhancement of apoptosis and reduction in proliferation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5615. doi:1538-7445.AM2012-5615
Comparison of an Antiinflammatory Dose of Ibuprofen, an Analgesic Dose of Ibuprofen, and Acetaminophen in the Treatment of Patients with Osteoarthritis of the Knee
Authors: John D. Bradley, Kenneth D. Brandt, Barry P. Katz, Lorrie A. Kalasinski, Sarah I. Ryan
Journal: New England Journal of Medicine (1991)

The optimal short-term, symptomatic therapy for osteoarthritis of the knee has not been fully determined. Accordingly, we compared the efficacy of a nonsteroidal antiinflammatory drug, ibuprofen, given in either an antiinflammatory dose (high dose) or an analgesic dose (low dose), with that of acetaminophen, a pure analgesic.
THU0394 Reduced Steroid Dosage Improves Bone Metabolic Markers in Patients with Rheumatoid Arthritis: The Tomorrow Study
Authors: M. Tada, T. Koike, T. Okano, Y. Sugioka, K. Mamoto, K. Inui, H. Nakamura
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) develop osteoporosis more frequently than healthy individuals. Bone resorption and formation are respectively increased and inhibited in patients with RA<sup>1</sup>, and steroids negatively affect bone metabolism in both patients with RA and healthy individuals. The effect of reducing the steroid dose on bone metabolic markers in patients with RA has remained unknown. <h3>Objectives</h3> To understand annual changes in bone metabolic markers in patients with RA and healthy volunteers and to identify bone metabolic markers for RA. <h3>Methods</h3> We started the 10-year prospective cohort TOMORROW (TOtal Management Of Risk factors in Rheumatoid arthritis patients to lOWer morbidity and mortality clinical trial (registration number, UMIN000003876)) in 2010. We compared changes in urinary crosslinked N-telopeptide of typeI collagen (NTx) and serum osteocalcin (OC), which are markers of bone resorption and formation, respectively, in a total of 404 age- and sex-matched patients and volunteersbetween 2010 and 2011 (ΔNTx = NTx during 2011 – NTx during 2010; ΔOC = OC during 2011 – OC during 2010). We also investigated the effects of decreasing the prednisolone (PSL) dosage on disease activity (ΔDAS28) for NTx and OC in the patients. <h3>Results</h3> The ΔNTx values were significantly lower in the patients than in the volunteers (-0.51 ± 29.4 vs. 7.41 ± 18.7 nmol; p=0.0013), whereas theΔOC values were significantly higher in the patients (0.94 ± 2.47 vs. 0.37 ± 1.62; p=0.0065). The change of PSL dosage negatively and positively correlated with ΔOC ((r=-0.227, p=0.001; Fig. 1) and ΔNTx (r=0.07, p=0.323; Fig. 2), respectively, in the patients, whereas ΔDAS28 did not significantly correlate with ΔOC or ΔNTx. <h3>Image/graph</h3> <h3>Conclusions</h3> A decrease in the dose of PSL respectively decreased and increased markers of bone resorption and formation in parallel among patients with RA. That is, bone metabolic makers were improved. However, bone metabolic makers and disease activity did not correlate. Thus, bone metabolic markers might degenerate even when disease activity is under good control. Decreasing the PSL dosage is important for bone metabolism in patients with RA. <h3>References</h3> Garnero P, Delmas PD. Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers. <i>Curr Opin Rheumatol</i>. 2004; 16:428-34. <h3>Disclosure of Interest</h3> M. Tada Grant/research support from: Japan Osteoporosis Foundation grant 2013, T. Koike Speakers bureau: Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Eisai, Abbott Japan, Teijin Pharma, Banyu Pharmaceutical and Ono Pharmaceutical, T. Okano: None Declared, Y. Sugioka: None Declared, K. Mamoto: None Declared, K. Inui: None Declared, H. Nakamura: None Declared
Abstract 5049: Serum miRNAs as an early marker for breast cancer
Authors: Ashley C. Godfrey, Zongli Xu, Clarice R. Weinberg, Paul A. Wade, Lisa A. Deroo, Dale P. Sandler, Jack A. Taylor
Journal: Cancer Research (2012)

Abstract MicroRNAs (miRNAs) are small, non-coding, single-stranded RNAs between 18-22 nucleotides that regulate gene expression by affecting mRNA translation and degradation. It has been proposed that miRNAs could be master regulators of gene expression by regulating entire gene networks. Expression of miRNAs is altered in tumor compared to normal tissue and there is growing evidence that miRNA profiles in serum may differ in cancer cases as compared to healthy controls. However, these studies use samples collected after diagnosis so treatment and/or disease effects cannot be excluded. We are using serum samples from the Sister Study, a prospective cohort study of 50,000 women who had never had breast cancer at the time of enrollment, but were at increased risk because they had a sister previously diagnosed with breast cancer. We are exploring whether serum miRNA profiles can be used as prediagnostic markers of breast cancer. In an initial pilot analysis comparing 5 women diagnosed with breast cancer 1-2 months after their blood draw to 5 controls, there were 25 miRNAs significantly different at the 0.05 level (paired T test). Of those 25 miRNAs, 7 have been previously associated with breast tumor tissue in published studies showing differential expression in tumor tissue or in breast cancer cell lines. We have now completed a larger follow up study examining 205 women diagnosed with breast cancer within 18 months of their blood draw compared to 205 controls frequency matched to cases by age, 2 month interval of blood draw and race. We are using Affymetrix miRNA microarrays to profile miRNA expression in serum samples, and have optimized this platform for use with less than .5mLs of serum. After normalization and background correction, we found 439 miRNAs (of 1105 human miRNAs on the chip) expressed above background in at least 50 samples. When the average expression of controls was compared to cases using logistic regression, we found 16 miRNAs significantly different at the .05 level. For cases, the mean time between blood draw and cancer diagnosis was 10 months. We hypothesize that, if miRNA is a prediagnostic marker, cases with a longer time between blood draw and diagnosis would have a more control-like miRNA profile. To examine this, we are conducting a more detailed analysis among cases with a short time between blood draw and diagnosis. The next steps of our analysis will be to examine how far in advance of cancer diagnosis can we detect case-control differences in miRNA expression profiles. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5049. doi:1538-7445.AM2012-5049
S27 Venous Bicarbonate As A Clinical Tool For Identifying Obesity Hypoventilation Syndrome In The Sleep Clinic
Authors: B. Prudon, S. West
Journal: Thorax (2014)

<h3>Introduction</h3> Obesity Hypoventilation Syndrome (OHS) is defined as sleep disordered breathing, obesity, and daytime hypercapnia, without another cause of ventilatory impairment. Literature suggests 10–25% of patients assessed for Obstructive Sleep Apnoea (OSA) have OHS, with significantly increased morbidity and mortality. Early identification may be beneficial. Studies suggest venous bicarbonate (vHCO<sub>3</sub><sup>-</sup>) ≥27 mmol/l can be used to screen for OHS. We assessed the impact of incorporating this measurement into patient assessments. <h3>Methods</h3> Obese out-patients referred for possible OSA had vHCO<sub>3</sub><sup>- </sup>measured. Patients with a vHCO<sub>3</sub><sup>-</sup> ≥27 mmol/l underwent arterial blood gas (ABG) analysis. Those with pCO<sub>2</sub> &gt;6.2 kPa underwent further assessments to identify the cause of ventilatory impairment. None had been referred specifically for investigation of OHS. Patients had domiciliary or in-patient sleep studies as per standard practice. <h3>Results</h3> There were 288 patients included: 65% males, mean (SD) age 50 years (range 21–79 years), BMI 39.2 kg/m<sup>2</sup> (7.8), Epworth Sleepiness Scale 13 (6), daytime SpO<sub>2</sub> on air 97% (2.1). Sleep study results showed the Apnoea-Hypopnea Index (AHI) to be ≥5 in 88%, and ≥30 in 49%. Mean vHCO<sub>3</sub><sup>-</sup> was 26.2 mmol/l (2.7). vHCO<sub>3</sub><sup>-</sup> correlated significantly (r = 0.3–0.4, p &lt; 0.005) with daytime SpO<sub>2</sub>, mean overnight SpO<sub>2</sub>, time spent &lt;80% and &lt;90%, but not AHI or ODI. vHCO<sub>3</sub><sup>-</sup> was ≥27 mmol/l in 123 (43%), of whom 80 had an ABG measurement; mean pCO<sub>2</sub> 5.4 kPa (0.8), ten patients &gt;6.2 kPa. Ventilatory impairment was due to OHS in four (5% of ABG cohort); there was additional lung or chest wall disease in the other six. Overall, 25 patients had a base excess ≥3. The vHCO<sub>3</sub><sup>-</sup> range was 28–36 mmol/l in patients with OHS, with a BMI range of 38–53 kg/m<sup>2</sup>. Three additional outpatients with BMI &gt;50 kg/m<sup>2</sup> were diagnosed with OHS on ABG without vHCO<sub>3</sub><sup>- </sup>measurement. ­ In all seven OHS patients, CPAP was initiated. One was non-compliant, four improved and two required home non-invasive ventilation due to non-improvement in ABG. <h3>Conclusions</h3> In this large cohort of patients assessed for OSA, 43% had a vHCO<sub>3</sub><sup>-</sup> ≥27 mmol/l indicating possible OHS, but only 5% were actually diagnosed with OHS. In isolation this strategy to identify OHS seems inefficient. An increased vHCO<sub>3</sub><sup>-</sup> in combination with sleep study data may be superior.
A COMBINATION OF 123I-BMIPP SPECT AND STRESS 201TL MYOCARDIAL PERFUSION SPECT AS A USEFUL PROGNOSTIC MARKER OF ASYMPTOMATIC PATIENTS WITH NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Authors: Toshiharu Takeuchi, Masahide Goto, Makoto Aita, Ayumi Date, Eitaro Sugiyama, Akiho Minoshima, Naka Sakamoto, Yasuko Tanabe, Nobuyuki Sato, Naoyuki Hasebe
Journal: Journal of the American College of Cardiology (2015)
Solitary Plasmacytoma in the Renal Pelvis on 18F-FDG and 11C-Acetate PET/CT
Authors: Guilan Hu, Yanru Ma, Yonghong Dang, Fang Li, Li Huo
Journal: Clinical Nuclear Medicine (2016)

A 70-year-old man was incidentally found to have an occupying lesion in the left renal pelvis by ultrasonography during a routine health examination. CT images suggested renal cell carcinoma. FDG PET/CT scan was acquired for staging. The images did not reveal any hypermetabolic metastases. However, the metabolic activity of the lesion in the right renal pelvis was not unambiguously determined because of interference of radioactive urine. C-acetate PET/CT, on the other hand, clearly revealed increased activity in the left renal pelvis. Pathological examination demonstrated solitary extraosseous plasmacytoma.
HOW MUCH DO THE NEW ATRIAL FIBRILLATION GUIDELINES AFFECT STROKE PREVENTION PRACTICE?
Authors: Enrique Padilla Campos, Eric R. Silverman, Nicole Pohlman, Benjamin Gastevich, Lynne Braun, Youping Deng, Li Yan, Kousik Krishnan, Richard Trohman, Annabelle Volgman
Journal: Journal of the American College of Cardiology (2015)
SP0130 How to Treat (HOT) Osteoarthritis – an Evidence Based Overview
Authors: M. Doherty
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> Published guidelines on management of osteoarthritis (OA) in general agree on the aims and objectives of management and emphasise the following: (1) an individualised management plan (2) consideration of core non-pharmacological interventions (education, weight loss if overweight or obese, regular strengthening and aerobic exercise, and reducing adverse mechanical factors) for every person with OA, and (3) selective use of other physical treatments and topical, oral or intra-articular pharmacological agents for adjunctive pain relief, as required. Guidelines also agree that people with OA who derive insufficient benefits from recommended conservative management should be referred early rather than late for consideration of surgical intervention before severe functional impairment has developed. Also, older age and comorbidity are not reasons to not refer a person with OA for surgery. Unfortunately there are several problems with the research evidence in OA. These include: the low effect size for pain relief (above placebo) from most treatments; difficulty in determining the effect size of many physical treatments in RCTs (including exercise and education) due to inability to blind participants or to construct suitable placebo or sham treatments; a relative paucity of RCTs on OA at sites other than the knee or hip; predominantly short-term rather than long-term trial designs; and an undue focus in RCTs on monotherapy rather than combined treatment approaches. However, a striking feature of RCTs is the substantial effect size of placebo which is often greater than the additional specific effect of an individual treatment. This non-specific contextual response occurs in clinical practice, and being aware of contextual response and ways of optimising this can lead to substantial improvements in patient-centred outcomes. This evidence-based review will cover the principles and practice of recommended management of OA, address the “treatment paradox” of treatments that are not recommended by guideline groups (e.g acupuncture and nutriceuticals in the UK) yet appear to work well in clinical practice, and highlight factors that enhance contextual response and improve the care of people with OA. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6152
PTU-075 Systematic Review And Meta-analysis: Sensitivity And Specificity Of Tc-99m Hmpao Labelled White Cell Scintigraphy In The Diagnosis Of Active Inflammatory Bowel Disease
Authors: CJM Williams, AC Ford, A Poullis
Journal: Gut (2014)

<h3>Introduction</h3> Technetium-99m hexamethylpropylene amine oxime (Tc-99m HMPAO) labelled white cell scintigraphy (WCS) is frequently used in the assessment of patients suspected of having active inflammatory bowel disease (IBD). However, no previous systematic review and meta-analysis has assessed the sensitivity, specificity, and positive and negative predictive values of this investigation in comparison with colonoscopy and histology. We therefore aim to present these data here. <h3>Methods</h3> The MEDLINE and EMBASE databases were searched to January 2014. Prospective and retrospective cross-sectional studies recruiting adults suspected of a new diagnosis or flare of IBD, and comparing Tc-99m HMPAO labelled WCS with colonoscopy and histology, were eligible. True positive, false positive, true negative and false negative findings were pooled. A random effects model was used to obtain overall data for sensitivity, specificity, and positive and negative predictive values with a 95% confidence interval (CI). <h3>Results</h3> We identified 15 eligible studies reporting data from 635 patients (174 Crohn’s disease, 164 ulcerative colitis, 136 non-IBD). In total 1300 bowel segments were examined with 698 true positives, 41 false positives, 461 true negatives and 100 false negatives. Sensitivity was 0.90 (95% CI 0.85 to 0.95), specificity was 0.91 (95% CI 0.87 to 0.94), positive predictive value was 0.95 (95% CI 0.92 to 0.97) and negative predictive value was 0.83 (0.76 to 0.89). <h3>Conclusion</h3> Tc-99m HMPAO labelled WCS is a sensitive and specific test for the diagnosis of active inflammatory bowel disease. Physicians may therefore find this a useful test for those in whom colonoscopy and histology are impractical or contraindicated. <h3>Disclosure of Interest</h3> None Declared.
LEFT VENTRICULAR REMODELING AND MYOCARDIAL MECHANICS OBTAINED BY 2D STRAIN FOR PROGNOSTIC EVALUATION OF CLINICAL IMPROVEMENT IN HEART FAILURE PATIENTS UNDERGOING PERCUTANEOUS MITRAL VALVE REPAIR
Authors: Mario Kasner, Oskar Galuszka, Susanne Rutschow, Wolfgang Poller, Ulf Landmesser, Michael C. Gross
Journal: Journal of the American College of Cardiology (2016)
P90 Vitamin D status improves following recovery from tuberculosis
Authors: KD Witt, DA Jolliffe, Z Wang, KE Thummel, PM Timms, CJ Griffiths, AR Martineau
Journal: Thorax (2013)

<h3>Introduction and Objectives</h3> Vitamin D deficiency associates with active tuberculosis, but the question of whether this arises as a cause or as a consequence of disease is controversial. Paired comparison of vitamin D status of TB patients at diagnosis and following recovery has potential to inform the debate, but such studies have not previously been conducted. <h3>Methods</h3> We conducted a longitudinal study comparing serum concentrations of vitamin D metabolites in TB patients at long-term follow-up vs. diagnosis. Participants diagnosed with pulmonary TB in 2007–9 were invited to attend a follow-up visit in 2012. Concentrations of 25-hydroxyvitamin D (25[OH]D, the measure of vitamin D status), 1α,25-dihydroxyvitamin D (1,25[OH]<sub>2</sub>D), 24R,25-dihydroxyvitamin D (24,25(OH)<sub>2</sub>D), 4β,25-dihydroxyvitamin D (4,25[OH]<sub>2</sub>D), calcium, albumin, parathyroid hormone (PTH) and vitamin D binding protein (DBP) were determined in serum samples collected at follow-up and at the time of TB diagnosis. Values at the two time points were compared using Student’s paired t-tests. <h3>Results</h3> Thirty-one participants were followed up between August 2012 and February 2013. Serum 25(OH)D concentrations were significantly higher post-recovery than at diagnosis (mean 29.7 vs. 12.2 nmol/L, p &lt; 0.0001). Participants also had higher mean serum concentrations of PTH, corrected calcium and 24,25(OH)<sub>2</sub>D post-recovery than at diagnosis (PTH, 4.97 vs. 2.78 pmol/L, p = 0.0003; corrected calcium, 2.50 vs. 2.45 mmol/L, p = 0.03; 24,25(OH)<sub>2</sub>D, 3.15 vs. 1.53 nmol/L, p = 0.004). No statistically significant differences in serum concentrations of 1,25(OH)<sub>2</sub>D, 4,25(OH)<sub>2</sub>D or DBP were seen between the two time points. Differences in serum concentrations of 25(OH)D at follow-up vs. baseline remained statistically significant after exclusion of 14 participants who were taking supplemental vitamin D at follow-up and / or who had increased their sun exposure since time of diagnosis (p = 0.005), and after exclusion of 17 participants whose baseline sample was taken from March to July inclusive (p = 0.0003). <h3>Conclusions</h3> Vitamin D status of TB patients improved after resolution of tuberculosis. This phenomenon was not explained by differences in vitamin D supplementation, self-reported sun exposure or season of sampling at follow-up vs. baseline. Our findings raise the possibility that vitamin D deficiency may be a consequence, as well as a cause, of active tuberculosis.